[go: up one dir, main page]

MX2023005928A - Moduladores de malt-1. - Google Patents

Moduladores de malt-1.

Info

Publication number
MX2023005928A
MX2023005928A MX2023005928A MX2023005928A MX2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A MX 2023005928 A MX2023005928 A MX 2023005928A
Authority
MX
Mexico
Prior art keywords
malt
modulators
compounds
formula
syndromes
Prior art date
Application number
MX2023005928A
Other languages
English (en)
Inventor
David Evans
Simon Richards
Peter Ray
Anthony Bradley
Chris Radoux
Catarina Santos
Jeremy Besnard
Andrew John Cooke
Gomez Sylvie Félicité
Lorène Nathalie Sabine Cazaux-Lerou
Marta Pinto
Sabrina Pucci
Claire Christiane Ginette Blanger
Original Assignee
Exscientia Ai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exscientia Ai Ltd filed Critical Exscientia Ai Ltd
Publication of MX2023005928A publication Critical patent/MX2023005928A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Holo Graphy (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una fuente de iluminación de precisión compacta que se monta en el dedo de un usuario para proporcionar iluminación localizada en tareas de precisión como intervenciones quirúrgicas y otras tareas realizadas en espacios oscuros o reducidos. Un marco de forma circular o arqueada se engasta al dedo y sujeta un alojamiento con una luz pequeña pero potente y brillante que se enfoca en una región predeterminada definida por el extremo del dígito que probablemente sea una región de actividad de un instrumento agarrado por el dígito.
MX2023005928A 2020-11-23 2021-11-23 Moduladores de malt-1. MX2023005928A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2018412.3A GB202018412D0 (en) 2020-11-23 2020-11-23 Malt-1 modulators ii
PCT/GB2021/053031 WO2022106857A1 (en) 2020-11-23 2021-11-23 Malt-1 modulators

Publications (1)

Publication Number Publication Date
MX2023005928A true MX2023005928A (es) 2023-09-07

Family

ID=74046962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005928A MX2023005928A (es) 2020-11-23 2021-11-23 Moduladores de malt-1.

Country Status (12)

Country Link
US (1) US20250051327A1 (es)
EP (1) EP4247492A1 (es)
JP (1) JP2023550122A (es)
KR (1) KR20230112678A (es)
CN (1) CN116528857A (es)
AU (1) AU2021381009A1 (es)
CA (1) CA3196526A1 (es)
CO (1) CO2023007626A2 (es)
GB (1) GB202018412D0 (es)
IL (1) IL303036A (es)
MX (1) MX2023005928A (es)
WO (1) WO2022106857A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
KR20250120432A (ko) * 2022-12-23 2025-08-08 얀센 파마슈티카 엔브이 Malt1 억제제
WO2025003414A1 (en) * 2023-06-30 2025-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2025059027A1 (en) * 2023-09-11 2025-03-20 Schrödinger, Inc. Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物
WO2025224298A1 (en) * 2024-04-26 2025-10-30 Janssen Pharmaceutica Nv Inhibitors of malt1 and methods of their use
WO2025223551A1 (en) * 2024-04-26 2025-10-30 Janssen Pharmaceutica Nv Formulations, crystalline forms and dosage regimens of a malt1 inhibitor
WO2026003043A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003039A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003049A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003045A1 (en) 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Synthesis of a malt1 inhibitor
WO2026003051A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Crystalline forms
WO2026017148A1 (zh) * 2024-07-19 2026-01-22 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
DE10132686A1 (de) * 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2006522127A (ja) * 2003-04-01 2006-09-28 スミスクライン ビーチャム コーポレーション イミダゾトリアジン化合物
ME01526B (me) * 2009-02-26 2014-04-20 Boehringer Ingelheim Int Jedinjenja kao b1 antagonisti bradikinina
GB0920382D0 (en) 2009-11-20 2010-01-06 Univ Dundee Design of molecules
US9029389B2 (en) * 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
UY34616A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
EP2817295B1 (en) * 2012-02-23 2017-11-01 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
JPWO2015098991A1 (ja) * 2013-12-26 2017-03-23 東レ株式会社 Ｎ−アルキルアミド誘導体及びその医薬用途
AP2016009487A0 (en) 2014-05-28 2016-10-31 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
PT3305785T (pt) * 2015-05-29 2021-10-13 Teijin Pharma Ltd Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável
US9708333B2 (en) * 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017081641A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
US10822415B2 (en) * 2016-01-28 2020-11-03 Inserm (Institut National De La Santéet De La Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
MX2019004859A (es) * 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
JP2018135274A (ja) * 2017-02-20 2018-08-30 Ａｇｃ株式会社 多環芳香族炭化水素を光触媒とするフルオロメチル基含有化合物の製造方法
JP6891047B2 (ja) * 2017-05-31 2021-06-18 国立大学法人 名古屋工業大学 光学活性トリフルオロメチル基含有アミノ酸誘導体の製造方法
WO2018226150A1 (en) * 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
TWI784213B (zh) 2018-11-28 2022-11-21 日商武田藥品工業股份有限公司 雜環化合物
CA3198715A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
WO2022081995A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof

Also Published As

Publication number Publication date
CO2023007626A2 (es) 2023-08-18
CN116528857A (zh) 2023-08-01
AU2021381009A1 (en) 2023-06-08
EP4247492A1 (en) 2023-09-27
CA3196526A1 (en) 2022-05-27
IL303036A (en) 2023-07-01
KR20230112678A (ko) 2023-07-27
AU2021381009A9 (en) 2024-07-25
GB202018412D0 (en) 2021-01-06
JP2023550122A (ja) 2023-11-30
WO2022106857A1 (en) 2022-05-27
US20250051327A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
MX2023005928A (es) Moduladores de malt-1.
MX2023013012A (es) Moduladores de proteina cinasa c (pkc)-theta.
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
PH12021552759A1 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
PH12020552206A1 (en) Pyrazole derivatives as malt1 inhibitors
MX2023013013A (es) Moduladores de proteina cinasa c (pkc)-theta.
PH12020552207A1 (en) Pyrazole derivatives as malt1 inhibitors
MY207223A (en) Prodrug modulators of the integrated stress pathway
CR20200243A (es) Modalidades de la via de estres integrada
MX2025007384A (es) Inhibidores de malt1
PH12021552555A1 (en) Dihydroorotate dehydrogenase inhibitors
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
MX2021012417A (es) Anillos de piridina que contienen derivados como inhibidores de malt1.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
WO2021226206A3 (en) Cannabinoid receptor type 2 (cb2) modulators and uses thereof
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MX2025007469A (es) Moduladores lsd1
MX2023003035A (es) Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme.
MX2021014582A (es) Derivados de diazepinona como moduladores del ensamblaje de la capside.
MX2021014580A (es) Derivados heterociclos condensados como moduladores de ensamblaje de la capside.
MX2021014577A (es) Difluoroazepanos como moduladores del ensamblaje de la cápside del vhb.
MX2021014578A (es) Azepinas como moduladores del ensamblaje de la cápside del vhb.